Back to School: How biopharma can reboot drug development. Access exclusive analysis here

141W94/VX-478 HIV protease inhibitor: VRTX and partner Glaxo Wellcome plc began a double-blind Phase III trial of 141W94 in combination with nucleoside analog t

Patients will continue to receive their other therapy and in addition will receive either placebo or

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers